Shanghai preps for $3B in drug-buying deals; Elliott backs Actelion board nominees;

@FiercePharma: Union urges votes against CEO pay at Pfizer, J&J. News | Follow @FiercePharma

> Shanghai Pharmaceuticals, one of China's biggest medicine companies, said it will ink more than 20 billion yuan ($3.06 billion) worth of procurement contracts with 69 multinational pharmaceutical companies this year. News

> Elliott Advisors, the biggest shareholder in Actelion, offered a partial olive branch to the Swiss biotech group by supporting its nomination of two new independent board members, including former GlaxoSmithKline CEO Jean-Pierre Garnier. Report

> Watson Pharmaceuticals will move its corporate headquarters to Parsippany, New Jersey from Corona, California. Item

> India's No. 2 drugmaker Dr. Reddy's Laboratories launched its over-the-counter Fexofenadine HCl tablets, a generic version of Sanofi Aventis' antihistamine drug Allegra. Article

> UK household-goods and consumer health company Reckitt Benckiser said Rakesh Kapoor will take over as CEO in September, replacing Bart Becht, who has quit after 16 years at the helm. Story

> The UK's Prescription Medicines Code of Practice Authority, which arbitrates drug industry self-regulation, issued "informal guidance" on digital communications, and while it's more than FDA has offered, it's not much to go on. Item

> New York Gov. Andrew Cuomo has signed into law a bill enabling OSI Pharmaceuticals to expand at Farmingdale State College. Report

> Bulgarian pharmaceuticals maker Sopharma has acquired the Belorussian pharmacy chain Tabina through its Latvian unit Briz. Article

> The New York Pharma Forum, a non-profit association for biopharmaceutical corporations, announced the election of Blaine McKee, SVP at Genzyme, as its president. NYPF release

Biotech News

 @FierceBiotech: Burrill: Pharma's M&A strategy has failed. News | Follow @FierceBiotech

> Regulus, UC San Diego team on microRNA. Story 

> Nasal vaccines could replace shots. Article 

> RegeneRx sets sights on dry-eye treatment. News 

> Does Eisai's epilepsy drug work? Yes and no. Report 

> Merrimack raises $77M for cancer work. News 

> Plasticell spins out regenerative medicine company. Item 

Vaccines News

> Personalized cancer vax shows promise against glioblastomas in study. Report 

> Nasal vaccines could replace flu, pneumonia shots. Item 

> HPV vax effective after longer dosing schedule. Article 

> Army researchers start ricin vaccine trial. News

> PATH calls for cheaper, more effective pneumococcal vaccines. Story 

Manufacturing News

> API crystals foul Hospira cancer drug. Item

> Ex-QC inspector alleges H&P/Triad plant violations. Report 

> COO search marks Triad/H&P effort on raided plant. News 

> FDA's OK of Perrigo plant signals SOP fixes. Item

And Finally... A new multiple sclerosis study debunks a theory about a potential cause for the disease, which had led patients to seek risky surgeries to unblock neck veins when drug treatments didn't work for them. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.